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MaDespite signiﬁcant advances in battery longevity, lead performance, and programming features since the ﬁrst implanted
permanent pacemaker was developed, the basic design of cardiac pacemakers has remained relatively unchanged
over the past 50 years. Because of inherent limitations in their design, conventional (transvenous) pacemakers are prone
to multiple potential short- and long-term complications. Accordingly, there has been intense interest in a system able
to provide the symptomatic and potentially lifesaving therapies of cardiac pacemakers while mitigating many of the
risks associated with their weakest link—the transvenous lead. Leadless cardiac pacing represents the future of cardiac
pacing systems, similar to the transition that occurred from the use of epicardial pacing systems to the familiar trans-
venous systems of today. This review summarizes the current evidence and potential beneﬁts of leadless pacing systems,
which are either commercially available (in Europe) or under clinical investigation. (J Am Coll Cardiol 2015;66:1179–89)
© 2015 by the American College of Cardiology Foundation.S ince the ﬁrst completely endocardial transve-nous permanent pacemaker was implantedmore than 50 years ago, signiﬁcant advances
have been made in battery longevity, lead perfor-
mance, and device programming (1–3). Nevertheless,
the basic design of cardiac pacemakers has remained
relatively unchanged: a (most commonly) pectoral
pulse generator connected to 1 or more transvenous
leads. Although highly reliable, conventional cardiac
pacemakers have several limitations. The subcutane-
ous pocket has a potential for local complications,
such as skin erosion and pocket hematomas, which
can be associated with a 15-fold higher risk for subse-
quent infection if early reintervention is required
(4–6). The insertion of transvenous leads can result
in acute complications, such as pneumothorax or up-
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obstruction, tricuspid valve insufﬁciency, and infec-
tion (7,8). Even for single-chamber transvenous sys-
tems (which are associated with a lower risk than
dual-chamber system implants), more than 1 in every
40 implants will result in a complication requiring
surgical intervention within the ﬁrst 3 months, of
which more than one-half are lead related (9,10). In
the long term, lead failures are associated with signif-
icant morbidity (7).
Early recognition that transvenous leads are the
weakest link of conventional pacing systems led in-
vestigators more than 40 years ago to consider the
possibility of leadless cardiac pacing (1). A pre-clinical
report in 1970 demonstrated the feasibility of a totally
self-contained intracardiac pacemaker. In that study,
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ABBR EV I A T I ON S
AND ACRONYMS
CRT = cardiac
resynchronization therapy
LCP = leadless cardiac
pacemaker
TPS = transcatheter pacing
system
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1180more than 2 months. The delivery catheter
was inserted through the jugular vein, the
leadless pacemaker was passed into the right
ventricle under ﬂuoroscopy, and radially
directed spiral barbs attached the cylindrical
device to the ventricular myocardium. Ap-
proximately 2 decades later, additional pre-
clinical testing again demonstrated thepotential feasibility of this approach (11). Although
the ﬁeld of leadless cardiac pacing remained stagnant
for almost 20 years, this has changed with the advent
of advancements in several areas, including catheter-
based delivery systems, miniaturized high-density
energy sources, low-power electronics, novel pack-
aging capabilities, and novel communication tech-
nologies. In this review, we strive to summarize the
current state of the 2 basic designs of leadless cardiac
pacemakers (LCPs). One design uses 2 separate com-
ponents, an endocardial pacing electrode and a sub-
cutaneous energy transmitter, whereas the second
design is a completely self-contained device in which
the pulse generator and pacing electrode are a single
component.
MULTICOMPONENT (NOT SELF-CONTAINED)
LEADLESS PACING
ULTRASOUND-MEDIATED ENERGY TRANSFER.
Recently, the results of WiSE-CRT (Wireless Stimula-
tion Endocardially for CRT), a prospective observa-
tional feasibility study of leadless ultrasound-based
endocardial left ventricular pacing in patients with
guideline-directed indication for cardiac resynchro-
nization therapy (CRT) were reported (12). The
WiSE-CRT study used a system intended for chronic
use with 2 components: a subcutaneous pulse ge-
nerator and a small receiver electrode. The subcu-
taneous pulse generator was surgically implanted in
the left lateral thorax (subcutaneous) and generated
ultrasonic acoustic energy; the small receiver elec-
trode was implanted directly onto the left ven-
tricular endocardium (using a retrograde aortic
approach) and converted the acoustic energy to
electric pacing pulses (13). All patients in WiSE-CRT
had existing implantable cardiac devices (pace-
makers or deﬁbrillators) and were considered
eligible for enrollment if they: 1) had undergone
prior failed coronary sinus lead implantation; 2) had
undergone previously successful placement of a
coronary sinus lead but were clinical nonresponders;
or 3) required an upgrade to a CRT system (12,14).
From an efﬁcacy perspective, the results of WiSE-
CRT were promising: left ventricular function
improved at 6 months (mean pre-implantation leftventricular ejection fraction of 25  4.0% vs. mean
6-month post-implantation ejection fraction of 31 
7.0%; p < 0.01). However, the study was terminated
prematurely for safety reasons. Of the 17 patients
enrolled (of an intended 100 patients), the device
could be successfully implanted in only approxi-
mately three-quarters (n ¼ 13 [76%]). Most impor-
tant, 3 patients (18%) developed serious procedure-
related pericardial effusions due to either delivery
sheath or guidewire manipulation; 1 of these resul-
ted in a patient’s death. Additionally, 2 patients
(11%) required revision of the transmitter position
because of loss of biventricular pacing, and in 1
patient, there was unexpected depletion of the
battery.
After WiSE-CRT was terminated because of safety
concerns, the delivery system was redesigned to
permit atraumatic implantation of the receiver elec-
trode onto the left ventricular endocardial surface.
Similar to that studied in WiSE-CRT, the redesigned
leadless system is also composed of an implanted
battery-powered ultrasonic transmitter and a leadless
pacing electrode implanted directly onto the left
ventricular endocardium (Figure 1). Again, the system
detects a right ventricular pacing pulse from a coim-
planted pacemaker or deﬁbrillator and delivers ul-
trasonic energy to the electrode, which transduces
the energy to an electric pacing pulse to stimulate the
left ventricle synchronously with the right ventricle.
The initial evaluation of this redesigned system in the
SELECT-LV (Safety and Performance of Electrodes
Implanted in the Left Ventricle) study revealed: 1)
adequate acoustic windows to permit implantation in
the majority of patients (12 of 14 [86%]); 2) signiﬁcant
cardiac resynchronization in all 12 implanted pa-
tients, with QRS shortening by 60  24 ms (vs. right
ventricular pacing); and, importantly, 3) no instances
of intraprocedural adverse events (15). The SELECT-
LV trial continues to enroll patients at multiple
centers in Europe.
Although the initial SELECT-LV data suggest that
the delivery system modiﬁcations have largely ad-
dressed the major procedural complication observed
in WiSE-CRT, there remain several technology-
speciﬁc concerns that require consideration. First,
although the left ventricular receiver component of
this system is indeed leadless, the system does
require the use of conventional transvenous leads,
because all patients required concomitant conven-
tional implantable right ventricular pacing devices.
Second, it is theoretically possible that long-term
ultrasound energy exposure to subcutaneous or
myocardial tissue in humans may have unintended
adverse consequences. Third, there may be untoward
FIGURE 1 The Leadless Endocardial Left Ventricular Pacing System
Anteroposterior (AP) (A) and lateral (LAT) (B) chest radiograph views of the implanted system, including battery, transmitter, and receiver/
pacing electrode (inset).
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1181effects of external (environmental) interference and
changes in the acoustic window on the system’s
sensing or pacing performance. In some patients, the
availability of an adequate acoustic window may
limit the response to resynchronization therapy,
because of either the location of the endocardial
receiver electrode (anterolateral or lateral-apical) or
the target location of the transmitter (intercostal
space, because acoustic energy is refracted by bone).
Fourth, compared with conventional power sources,
energy transfer of current ultrasound-mediated
pacing systems is inefﬁcient and might result in a
comparatively short battery life (16,17). In fact, in
WiSE-CRT, at the 6-month post-implantation follow-
up visit, the remaining battery life projection was a
mean of 18 months (range: 9 to 42 months). Finally,
the endoluminal left ventricular positioning of the
receiver electrode could predispose to thromboem-
bolic complications. Indeed, in SELECT-LV, 1 patient
with atrial ﬁbrillation in whom oral anticoagulation
was interrupted for the procedure sustained a stroke.
In subsequent cases, oral anticoagulation was not
interrupted (at operator discretion) for the procedure,
and no subsequent strokes were observed; however,
the safety of this strategy needs to be validated in a
larger cohort of patients. However, it should be noted
that in a study that used a different approach to left
ventricular endocardial pacing (using a transseptal
approach), 14% patients (7 of 51) experienced throm-
boembolic events (stroke or transient ischemic
attack) during follow-up (18). However, most of thesepatients had subtherapeutic anticoagulation at the
time of the event (the goal international normalized
ratio was 3.5 to 4.5), and this risk would certainly be
expected to be less with the smaller volume leadless
electrodes associated with the multicomponent sys-
tems. However, this potential for thromboembolic
complications remains important to test in large
clinical trials.
However, there are compelling data indicating a
potentially signiﬁcant clinical beneﬁt to leadless left
ventricular endocardial pacing. Endocardial left ven-
tricular pacing is more physiological (endocardial-
to-epicardial transmural activation sequence), may
enhance left ventricular diastolic and systolic perfor-
mance, has the potential to be less proarrhythmic
(reduced dispersion of ventricular repolarization), and
likely requires lower pacing energy outputs compared
with optimally placed coronary sinus leads (19,20).
Furthermore, because it is not limited to those coro-
nary sinus branches able to accommodate a trans-
venous lead, endocardial pacing offers a larger choice
of optimal left ventricular stimulation sites; there is
also the added beneﬁt of no phrenic nerve stimulation.
Leadless left ventricular endocardial pacing might
mitigate these limitations and expand our ability to
provide optimal CRT. However, there are other vari-
ables, such as endocardial scar and adjacent struc-
tures, including the papillary muscles, that may affect
the ability to pace at the optimal endocardial location
(21). Finally, and most important, 2 independent ran-
domized controlled trials, TARGET (Targeted Left
FIGURE 2 The Single-Component (Fully Self-Contained)
Leadless Pacemakers
The Micra Transcatheter Pacing System (left) and Nanostim
leadless cardiac pacemaker (right) are shown next to a ruler.
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Resynchronization Therapy) and STARTER (Speckle
Tracking Assisted Resynchronization Therapy for
Electrode Region), demonstrated that better targeting
of the left ventricular pacing site (at the site of latest
contraction or ventricular activation) leads to im-
provements in clinical response, including freedom
from heart failure hospitalization or mortality (22,23).
Indeed, because of these various potential advantages
to left ventricular endocardial pacing, several in-
vestigators have attempted left ventricular endocar-
dial pacing with standard transvenous leads (placed
transseptally across the mitral valve directly into the
left ventricle) for nonresponders or those with inac-
cessible coronary sinus anatomy. Although technically
feasible, its widespread adoption has been limited
by the complexity of the procedure, the need for
aggressive chronic oral anticoagulation (with a rec-
ommended target international normalized ratio of
3.5 to 4.5), and potential adverse consequences, such
as the long-term effect on the mitral valve (24).
Leadless left ventricular endocardial pacing might
mitigate these risks and expand our ability to provide
optimal CRT.
INDUCTION TECHNOLOGY. Leadless pacing using
induction (electromagnetic) technology also consists
of at least 2 components: a subcutaneous (or sub-
muscular) transmitter unit located just above the
heart and a receiver unit implanted into the ventric-
ular endocardium (25). Brieﬂy, the transmitter gen-
erates an alternating magnetic ﬁeld, of which a
fraction is converted to stimulatory voltage pulses
by the receiver unit. Although leadless pacing using
induction may be feasible, it has been tested only
in animal models (porcine and goat), and further
work is needed to determine the effects of align-
ment, distance, and external interferences on this
technology (26).
SINGLE-COMPONENT
(FULLY SELF-CONTAINED) LEADLESS PACING
With single-component LCPs, the pulse generator and
sensing/pacing electrodes are fully contained within
a single unit, thereby eliminating the leads, pectoral
surgical pockets, and intrasystem connections. The
device is delivered to the right ventricle with a cath-
eter through the femoral vein. At present, 2 types of
single-unit leadless pacemakers have been implanted
in humans: the Nanostim LCP (St. Jude Medical, Inc.,
St. Paul, Minnesota) and, more recently, the Micra
Transcatheter Pacing System (TPS) (Medtronic, Inc.,
Minneapolis, Minnesota).The LCP has CE Mark approval for European use
but remains investigational in the United States,
whereas the TPS is investigational in both Europe
and the United States. Comparatively, the TPS (25.9 
6.7 mm) is shorter but wider than the LCP (42 
5.99 mm); accordingly, the outer diameter of the de-
livery sheath for the TPS is larger (24-F) than that for
the LCP (18-F). Of course, both devices are signiﬁ-
cantly smaller than conventional single-chamber
transvenous pacemakers (approximately one-tenth
the volume); this size discrepancy is further accen-
tuated by the fact that the volume displaced
by the pacing lead is typically not factored into
these comparisons. Examples of both devices are
shown in Figure 2, and the 2 devices are compared
in Table 1.
With regard to ﬁxation mechanisms, the LCP uses
an active screw-in helix and a secondary ﬁxation
mechanism consisting of 3 angled nitinol tines
perpendicular to the helix, whereas the TPS uses 4
self-expanding nitinol tines to afﬁx to the myocar-
dium. Figure 3 shows an example of an implantation
of an LCP that was repositioned acutely prior to being
disconnected from the delivery catheter; it was then
TABLE 1 Characteristics of the LCP and TCP
Parameter LCP TCP
Polarity Bipolar Bipolar
Pacing modes VVI (R) VVI (R)
Rate modulation mechanism Blood temperature 3-axis accelerometer
Battery technology Lithium carbon monoﬂuoride Lithium silver vanadium
oxide / carbon monoﬂuoride
Programmer St. Jude Medical, model 3650 Medtronic, model 2090
Energy capacity (mAh) 248 120
Estimated longevity
ISO standard, yrs* 9.8 yrs 4.7 yrs
Alternative setting, yrs† 14.7 yrs 9.6 yrs
Size (h  w), maximum
thickness, mm
42 mm  5.99 mm 25.9 mm  6.7 mm
Volume (cc) 1.0 0.8
Fixation mechanism Helix (screw-in) Tines
*Longevity based on ﬁxed programming at the ISO International Organization for Standardization (ISO 14708)
standard guidelines for reporting pacemaker battery duration longevity: 2.5 V, 0.4 ms, 600 U, 60 beats/min,
and 100% pacing. †Longevity based on nominal settings (for the TCP): 1.5 V, 0.24 ms, 60 beats/min (with an
impedance load of 500 ohms and 100% pacing).
LCP ¼ leadless cardiac pacemaker; TCP ¼ transcatheter pacing system.
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1183positioned at an alternative apical septal location to
achieve stable and durable sensing and pacing pa-
rameters. Figure 4 shows an example of the protective
sleeve, ﬁxation mechanism, and bipolar sensing and
pacing conﬁguration of the TPS. Both devices use
a tethering mechanism to maintain a connection
between the delivery catheter and the device to test
positional integrity before ﬁnal deployment. Figure 5
shows an example of a TPS implantation. Finally,
both devices are reportedly retrievable, although only
animal data with the LCP exist to demonstrate the
feasibility of chronic extraction. Figure 6 shows ﬂuo-
roscopic images from a clinical case of acute retrieval
of an LCP that had been inadvertently implanted in
the left ventricle (through a patent foramen ovale). To
minimize the possibility of inadvertent placement of
the device into the left ventricle through a patent
foramen ovale, left anterior oblique ﬂuoroscopic
imaging should be performed prior to device release.
The LEADLESS trial, a ﬁrst-in-human, single-arm,
multicenter study of the safety and clinical perfor-
mance of the LCP, was recently reported (27).
Brieﬂy, patients were considered eligible if they had
indications for single-chamber, right ventricular
pacing (VVI [R]). Indications included: 1) perma-
nent atrial ﬁbrillation with atrioventricular block
(including atrial ﬁbrillation with a slow ventricular
response); 2) normal sinus rhythm with second- or
third-degree atrioventricular block with a low level
of physical activity or short expected life span; and
3) sinus bradycardia with infrequent pauses or un-
explained syncope with electrophysiologic ﬁndings.
Exclusion criteria comprised pacemaker de-
pendency, signiﬁcant pulmonary hypertension, or
pre-existing mechanical tricuspid valve prosthesis,
pacemaker/deﬁbrillator leads, or inferior vena cava
ﬁlter. Thirty-three patients were enrolled in the
LEADLESS trial. The implantation success rate was
97% (32 of 33 patients), the mean procedure duration
was 28  17 min, and the overall complication-free
rate was 94% (31 of 33 patients). The 2 complica-
tions were right ventricular perforation/cardiac
tamponade (the patient subsequently died of a
stroke) and inadvertent placement of the device
through a patent foramen ovale (the device was
retrieved in the same procedure, and no disability
resulted). After 3 months of follow-up, all measures
of pacing performance (lead impedance, pacing, and
sensing threshold) either improved or were stably
within the acceptable range.
The 1-year follow-up results of the LEADLESS trial
were recently reported and demonstrated that: 1)
performance measures (pacing threshold, impedance,
and sensing) remained stable; 2) there were furtherno complications related to the device (beyond the
index procedure); 3) there were no premature battery
depletions or under/oversensing issues; and 4)
adequate rate response, deﬁned as 80% of the pre-
dicted maximal heart adjusted for age, was observed
in those patients for whom it was activated (n ¼ 19 of
30) (28). LEADLESS II is a large (n ¼ 600) prospective,
nonrandomized, single-arm, multicenter trial that
has recently begun to assess the clinical safety and
effectiveness of the LCP. This trial is intended to
provide sufﬁcient safety and long-term effectiveness
data to gain U.S. Food and Drug Administration reg-
ulatory approval. Similarly, a single-arm, multicenter
clinical trial assessing the TPS is also ongoing, and
although no results are yet available, the in-
vestigators intend to enroll up to 780 patients. Again,
these data will be used to support Food and Drug
Administration approval.
The early results of the Micra Transcatheter Pacing
System Study, a prospective, multicenter, single-arm
trial were recently reported. Similar to the LEADLESS
trial, patients were eligible if they had a Class I or II
indication for single-chamber right ventricular pac-
ing. The device was successfully implanted in all
patients (n ¼ 140 implanted patients). With regards to
early safety performance, 26 patients (18.6%) expe-
rienced either a protocol-deﬁned procedure or sys-
tem-related adverse event, including 4 patients with
transient atrioventricular block, 2 with ventricular
tachycardia, 1 with ventricular ﬁbrillation and 1 with
pericardial effusion without tamponade. There were
no procedure-related deaths or unanticipated serious
FIGURE 3 Implantation of the LCP
(A) The delivery catheter and leadless cardiac pacemaker (LCP) positioning in the right ventricular (RV) apex in the right anterior oblique (RAO)
view (contrast injection through the delivery sheath). (B) Positional integrity testing with traction applied to the LCP (tug test), while the device
remains tethered to the delivery catheter. After this maneuver, it was noted that the R waves declined from a baseline of 8.0 to 3.0 mV.
Accordingly, the LCP was redocked, and a new position was chosen (higher on the apical septum). (C) Delivery catheter and LCP positioning at
the RV apical septum (contrast injection through delivery sheath). (D) Final positioning of the LCP in the RAO view. At this location, the R waves
remained stable (>12.0 mV) at the end of the procedure and through 6 months of follow-up.
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1184adverse device events. With regards to early efﬁcacy
(n ¼ 60 patients, who had been followed for 3
months), as compared to baseline, the mean electrical
values for R-wave sensing amplitude, pacing imped-
ance, and pacing capture threshold were stable at
3-months. The full trial results (n ¼ 720 implanted
patients) are anticipated in 2016 (29).
POTENTIAL BENEFITS OF
LEADLESS CARDIAC PACING
As its name implies, the most obvious potential
beneﬁt of leadless cardiac pacing is the absence of a
transvenous lead. Because the majority of acute and
chronic complications of conventional pacemakers
are attributable to the transvenous lead, a system thateliminates this component is desirable (30). In addi-
tion to mitigating the risk of well-recognized com-
plications, such as lung injury during subclavian
access or chronic venous occlusion, there is also
the inherent beneﬁt of preventing intrasystem
connection errors (albeit an uncommon cause of
acute procedural complications), because the pulse
generator pace/sense electrodes are a single unit.
The single-component systems do not require a sur-
gical incision/subcutaneous pocket, which mitigates
the risk of surgical complications and may provide a
more favorable cosmetic proﬁle.
Despite their smaller size, LCPs have projected
battery longevity that is comparable to that of
standard single-chamber transvenous pacemakers.
One of the most important determinants of battery
FIGURE 4 Fixation Mechanism of the Transcatheter Pacing System
Protective Sleeve Being
Withdrawn –
Tines Extending 
Tines Completely Retroflexed –
Micra Still In Sheath
Sleeve Withdrawn –
Micra Remains Tethered at
Delivery Tool Interface
Tines
The sequence of images demonstrates the deployment of the tines as the pacemaker exits
the delivery sheath.
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1185longevity is the internal current drain. The current
drain for the LCP is only approximately 1 mA, which
is signiﬁcantly less than for a standard single-
chamber transvenous pacemaker (6.24 mA) from the
same manufacturer (31–33). Additional factors ac-
counting for the extended longevity of the leadless
pacemakers include the lack of “lost” energy
through the lead, the high-density lithium carbon
monoﬂuoride battery, and, importantly, for the LCP,
the use of energy-efﬁcient conductive (vs. inductive)
telemetry.
The battery life of the TCP, based on the Inter-
national Organization for Standardization (ISO)
standard for reporting battery longevity (2.5 V, 0.4
ms, 600 U, 60 beats/min, and 100% pacing) is
approximately one-half that of the LCP (Table 1)
largely because: 1) its smaller form factor also re-
sults in less battery capacity (248 vs. 120 mAh); and
2) instead of conductive telemetry, it employs radi-
ofrequency telemetry which results in a greater
background current drain. However, the TCP em-
ploys various energy-efﬁcient approaches to mini-
mize battery drain, such as capture management,
which would increase battery longevity. As an
example, the projected battery life for the TCP at the
nominal settings (1.5 V, 0.24 ms, 60 beats/min with
an impedance load of 500 ohms and 100% pacing)
increases to 9.6 years. In comparison, the LCP device
at the same settings has a projected battery life of
14.7 years. Finally, it should be also noted that the
energy efﬁciency of both the LCP and TCP are partly
related to the fewer enhancements (e.g., electrogramFIGURE 5 Implantation of the Transcatheter Pacing System
(A) The delivery sheath and pacemaker positioned at the right ventricul
(C) Positional integrity testing (tug test), while maintaining the connectstorage) in these devices, as compared with con-
ventional pacemakers.
The power source of the TPS device is lithium-
silver vanadium oxide/carbon monoﬂuoride, com-
monly used in transvenous systems. A high-densityar apex. (B) Tines have been exposed, and the cathode has engaged with the myocardium.
ion between the pacemaker and the delivery sheath. RAO ¼ right anterior oblique.
FIGURE 6 Retrieval of a Deployed LCP Device
The leadless cardiac pacemaker (LCP) had been inadvertently deployed within the left ventricle through a patent foramen ovale and thus required removal. (A) A trilobed
retrieval snare was advanced through the patent foramen ovale, across the mitral valve, and looped around the body of the LCP within the left ventricle. (B) The trilobed
snare was secured to the docking port on the distal end of the LCP. (C) After re-engagement of the delivery catheter to the docking port, the delivery sheath was drawn
back over the LCP. Subsequently, the LCP was unscrewed from the myocardium and removed from the left ventricle, and a new LCP was placed in the right ventricle.
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Although this is an ideal power source for miniatur-
ized leadless pacemakers because of its high energy
capacity, prior applications were limited by concerns
for abrupt end-of-service characteristics. However,
technological developments (including a proprietary-
algorithm fuel gauge to accurately predict the
remaining energy capacity of the cell) have ensured
that that the leadless pacemaker conforms to the In-
ternational Organization for Standardization
requirement that the device provide pacing function
for at least 6 months from the recommended
replacement time to end of service (34,35). The LCP
and TPS are also believed to be safe for use with
magnetic resonance imaging (conditionally), because
of their lack of ferrous material; however, additional
pre-clinical and clinical testing is necessary to
conﬁrm this. Finally, because of the greater distance
between the radiograph source and the operator
(located at the femoral insertion site) during LCP
implantation, there is potentially less radiation
exposure for the implanting physician. However,
there are currently no comparisons in total radiation
exposure between leadless pacemaker implants and
conventional transvenous systems.
POTENTIAL LIMITATIONS OF
LEADLESS CARDIAC PACING
For the current generation of single-unit LCPs,
the most important limitation is their ability to
perform only single-chamber pacing, speciﬁcallyright ventricular pacing. Therefore, these devices
would not be appropriate for most patients with
sinus node dysfunction, who derive signiﬁcant
clinical beneﬁt from dual-chamber sensing/pacing
(30). Although multichamber systems (atrioventric-
ular and biventricular) are in development, there
are currently no available data on the feasibility of
these systems. Device-device communication and
ﬁxation mechanisms (in the morphologically
distinct right atrium) are just a few of the chal-
lenges that must be overcome before multicom-
ponent systems can become a reality (Central
Illustration). To our knowledge, there have not
been any chronic device embolizations with single-
component systems, but this remains a potential
source of concern. The optimal ﬁxation mechanism,
with regard to both chronic performance and the
need for future extraction, remains to be seen. The
long-term reliability and accuracy of rate-responsive
features, now that the sensor has been relocated
from the subcutaneous pulse generator to the intra-
ventricular space, is not yet known. However, the
ongoing LEADLESS II trial is assessing rate-response
characteristics (as a secondary endpoint) in a series
of patients undergoing graded exercise testing.
Furthermore, although the single-component sys-
tems are, by volume, signiﬁcantly smaller than
conventional cardiac pacemakers, the portion of the
device that interacts with the endocardium has a
wider diameter, which has raised the possibility of
proarrhythmia. The delivery system for single-unit
leadless pacemakers includes a large venous sheath
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1187(24-F for the TPS and 18-F for the LCP) and delivery
catheter. The larger caliber of the delivery units has
the potential to increase complications related to
either the femoral access site or catheter manipulation
within the right ventricle. Indeed, in the LEADLESS
study, the one and only major procedural complica-
tion (cardiac perforation and subsequent death) was
related to the delivery catheter. Further reﬁnements
in technique and technology are likely to mitigate the
chance of this complication. Although leadlesspacemakers are reportedly retrievable acutely, the
ability to remove a chronically-implanted device re-
mains untested in humans. As such, the strategy for
device management (retrieval vs. abandonment) once
the battery has been depleted remains to be deter-
mined. As with any emerging technology, special
training will be required to develop proﬁciency
in LCP implantation. On one hand, many of the
technical and cognitive skills overlap with those
used in common electrophysiologic procedures (e.g.,
Miller et al. J A C C V O L . 6 6 , N O . 1 0 , 2 0 1 5
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1188ﬂuoroscopic imaging, manipulation and implantation
of devices within the right ventricle); on the other
hand, additional skills will undoubtedly require
further proctoring/training (e.g., large venous
sheaths, intraprocedural positional integrity testing).
Future clinical competency statements will likely
address this matter (36).
CONCLUSIONS
As with any transformative technology, a number of
questions remain unanswered with each of these
leadless pacing systems. Randomized clinical trials
will be necessary to deﬁnitively determine whetherthe theoretical beneﬁts of leadless systems will be
superior to those of conventional pacemakers both
from a safety perspective (fewer acute and chronic
complications) and in terms of long-term pacing and
sensing performance. However, it certainly seems
possible that the future of cardiac pacing will see the
minimization, if not eventual extinction, of all pacing
leads.
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